Skip to main content
Top
Published in: Obesity Surgery 5/2009

01-05-2009 | Research Article

Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis

Authors: J. Michael Estep, Ancha Baranova, Noreen Hossain, Hazem Elariny, Kathy Ankrah, Arian Afendy, Vikas Chandhoke, Zobair M. Younossi

Published in: Obesity Surgery | Issue 5/2009

Login to get access

Abstract

Background

White adipose tissue (WAT) from visceral adiposity plays an important role in the pathogenesis of non-alcoholic steatohepatitis (NASH). Development of NASH and its progression to fibrosis is partially due to cytokines and adipokines produced by WAT. The aim of this study was to assess the association of hepatic fibrosis and NASH by evaluating the intrinsic differences in the inflammatory cytokine signaling in the visceral adipose tissue obtained from morbidly obese patients.

Methods

We used targeted microarrays representing human genes involved in the inflammatory and fibrogenic reactions to profile visceral adipose samples of 15 well-matched NASH patients with and without fibrosis. Additionally, visceral adipose samples were subjected to real-time polymerase chain reaction profiling of 84 inflammations related genes.

Results

Eight genes (CCL2, CCL4, CCL18, CCR1, IL10RB, IL15RA, and LTB) were differentially expressed in NASH with fibrosis. Additionally, an overlapping but distinct list of the differentially expressed genes were found in NASH with type II diabetes (DM; IL8, BLR1, IL2RA, CD40LG, IL1RN, IL15RA, and CCL4) as compared to NASH without DM.

Conclusions

Inflammatory cytokines are differentially expressed in the adipose tissue of NASH with fibrosis, as well in NASH with DM. These findings point at the interaction of adipose inflammatory cytokines, DM, hepatic fibrosis in NASH, and its progression to cirrhosis and end-stage liver disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol. 2005;17:823–6.CrossRef Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol. 2005;17:823–6.CrossRef
2.
go back to reference Ong J, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in obese patients. Obes Surg. 2005;15(3):310–15.CrossRef Ong J, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in obese patients. Obes Surg. 2005;15(3):310–15.CrossRef
3.
go back to reference Nugent C, Bai CH, Elariny H, et al. Improvement of metabolic syndrome after laparoscopic bariatric surgery. Obes Surg. 2008;18(10):1278–86.CrossRef Nugent C, Bai CH, Elariny H, et al. Improvement of metabolic syndrome after laparoscopic bariatric surgery. Obes Surg. 2008;18(10):1278–86.CrossRef
4.
go back to reference Baranova A, Gowder SJ, Schlauch K, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16:1118–25.CrossRef Baranova A, Gowder SJ, Schlauch K, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16:1118–25.CrossRef
5.
go back to reference Baranova A, Schlauch K, Elariny H, et al. Gene expression patterns in the hepatic tissue and in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg. 2007;17(8):1111–8.CrossRef Baranova A, Schlauch K, Elariny H, et al. Gene expression patterns in the hepatic tissue and in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg. 2007;17(8):1111–8.CrossRef
6.
go back to reference Baranova A, Collantes R, Schlauch K, et al. A comparison of serum levels and gene expression of leptin, resistin and adiponectin in the adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16(9):1118–25.CrossRef Baranova A, Collantes R, Schlauch K, et al. A comparison of serum levels and gene expression of leptin, resistin and adiponectin in the adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16(9):1118–25.CrossRef
7.
go back to reference Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005;5:70–5.CrossRef Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005;5:70–5.CrossRef
8.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–9.CrossRef Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–9.CrossRef
9.
go back to reference Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1844–50.CrossRef Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1844–50.CrossRef
10.
go back to reference Gramlich T, Kleiner DE, McCullough AJ, et al. Pathologic features associated with fibrosis in non-alcoholic fatty liver disease. Human Pathol. 2004;35:196–99.CrossRef Gramlich T, Kleiner DE, McCullough AJ, et al. Pathologic features associated with fibrosis in non-alcoholic fatty liver disease. Human Pathol. 2004;35:196–99.CrossRef
11.
go back to reference Sasaki N, Ueno T, Morita Y, et al. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology 2006;53:678–81.PubMed Sasaki N, Ueno T, Morita Y, et al. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology 2006;53:678–81.PubMed
12.
go back to reference Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. J Clin Gastroenterol. 2006;40:S5–10. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. J Clin Gastroenterol. 2006;40:S5–10.
13.
go back to reference Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645–53.CrossRef Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645–53.CrossRef
14.
go back to reference Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21:3113–35.CrossRef Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21:3113–35.CrossRef
15.
go back to reference Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74:443–77.CrossRef Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74:443–77.CrossRef
16.
go back to reference You T, Nicklas BJ. Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr Diabetes Rev. 2006;2:29–37.CrossRef You T, Nicklas BJ. Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr Diabetes Rev. 2006;2:29–37.CrossRef
17.
go back to reference Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21.CrossRef Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21.CrossRef
18.
go back to reference Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose. Nutr Rev. 2007;65:S152–56.CrossRef Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose. Nutr Rev. 2007;65:S152–56.CrossRef
19.
go back to reference Fain JN, Madan AK. Regulation of monocyte chemoattractant protein 1 (mcp-1) release by explants of human visceral adipose tissue. Int J Obes (Lond). 2005;29:1299–307.CrossRef Fain JN, Madan AK. Regulation of monocyte chemoattractant protein 1 (mcp-1) release by explants of human visceral adipose tissue. Int J Obes (Lond). 2005;29:1299–307.CrossRef
20.
go back to reference Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol. 2007;18:258–62.CrossRef Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol. 2007;18:258–62.CrossRef
21.
go back to reference Kanno K, Tazuma S, Nishioka T, et al. Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci. 2005;50:942–8.CrossRef Kanno K, Tazuma S, Nishioka T, et al. Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci. 2005;50:942–8.CrossRef
22.
go back to reference Zeyda M, Farmer D, Todoric J, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond). 2007;31:1420–28.CrossRef Zeyda M, Farmer D, Todoric J, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond). 2007;31:1420–28.CrossRef
23.
go back to reference Cipollone F, Chiarelli F, Davì G, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005;48:1216–224.CrossRef Cipollone F, Chiarelli F, Davì G, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005;48:1216–224.CrossRef
24.
go back to reference Afford SC, Ahmed-Choudhury J, Randhawa S, et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J. 2001;15:2345–54.CrossRef Afford SC, Ahmed-Choudhury J, Randhawa S, et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J. 2001;15:2345–54.CrossRef
25.
go back to reference Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372–79.CrossRef Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372–79.CrossRef
26.
go back to reference Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010–13.CrossRef Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010–13.CrossRef
Metadata
Title
Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis
Authors
J. Michael Estep
Ancha Baranova
Noreen Hossain
Hazem Elariny
Kathy Ankrah
Arian Afendy
Vikas Chandhoke
Zobair M. Younossi
Publication date
01-05-2009
Publisher
Springer New York
Published in
Obesity Surgery / Issue 5/2009
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-009-9814-x

Other articles of this Issue 5/2009

Obesity Surgery 5/2009 Go to the issue